BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 9333041)

  • 1. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.
    Patick AK; Boritzki TJ; Bloom LA
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2159-64. PubMed ID: 9333041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication.
    Deminie CA; Bechtold CM; Stock D; Alam M; Djang F; Balch AH; Chou TC; Prichard M; Colonno RJ; Lin PF
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1346-51. PubMed ID: 8725999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents.
    Gulick R
    AIDS; 1998; 12 Suppl 3():S17-22. PubMed ID: 15168719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.
    Barry M; Mulcahy F; Merry C; Gibbons S; Back D
    Clin Pharmacokinet; 1999 Apr; 36(4):289-304. PubMed ID: 10320951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.
    Robinson BS; Riccardi KA; Gong YF; Guo Q; Stock DA; Blair WS; Terry BJ; Deminie CA; Djang F; Colonno RJ; Lin PF
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2093-9. PubMed ID: 10898681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
    Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM
    AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro.
    Hoggard PG; Manion V; Barry MG; Back DJ
    Br J Clin Pharmacol; 1998 Feb; 45(2):164-7. PubMed ID: 9491831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
    Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
    J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New developments in anti-HIV chemotherapy.
    De Clercq E
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):258-75. PubMed ID: 12084468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
    Eshleman SH; Krogstad P; Jackson JB; Wang YG; Lee S; Wei LJ; Cunningham S; Wantman M; Wiznia A; Johnson G; Nachman S; Palumbo P
    J Infect Dis; 2001 Jun; 183(12):1732-8. PubMed ID: 11372025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
    Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs.
    Mayers DL
    Am J Med; 1997 May; 102(5B):70-5. PubMed ID: 9845501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
    Rusconi S; La Seta Catamancio S; Sheridan F; Parker D
    J Clin Virol; 2000 Dec; 19(3):135-42. PubMed ID: 11090748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
    Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
    AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.
    Figgitt DP; Plosker GL
    Drugs; 2000 Aug; 60(2):481-516. PubMed ID: 10983742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
    Kuritzkes DR; Bassett RL; Johnson VA; Marschner IC; Eron JJ; Sommadossi JP; Acosta EP; Murphy RL; Fife K; Wood K; Bell D; Martinez A; Pettinelli CB
    AIDS; 2000 Jul; 14(11):1553-61. PubMed ID: 10983642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART.
    Paolucci S; Baldanti F; Maserati R; Castelli F; Suter F; Maggiolo F; Pan A; Gerna G
    Antiviral Res; 2000 Feb; 45(2):101-14. PubMed ID: 10809019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro.
    Hoggard PG; Sales SD; Kewn S; Sunderland D; Khoo SH; Hart CA; Back DJ
    Antivir Chem Chemother; 2000 Nov; 11(6):353-8. PubMed ID: 11227992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.